Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 6/20 | 0.49 |
| ▸ | RORC | P51449 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 3/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005281 | 0.93 | RORC (0.53) | CPT1ARORC | |
| SCHEMBL1998580 | 0.92 | CPT1A (0.48) | CPT1ARORCALDH1A1PKMCYP2C9 | |
| SCHEMBL2009465 | 0.91 | CPT1A (0.57) | CPT1ARORCCPT2CPT1B | |
| SCHEMBL1999909 | 0.88 | RORC (0.55) | CPT1ARORCCYP2C9CPT2CPT1B | |
| SCHEMBL1999577 | 0.88 | CPT1A (0.51) | CPT1ARORCPKMCYP2C9CPT2 | |
| SCHEMBL2000318 | 0.87 | RORC (0.49) | CPT1ARORCCYP2C9CPT2CPT1B | |
| SCHEMBL1999198 | 0.86 | CPT1A (0.49) | CPT1ARORCPKMCYP2C9CPT2 | |
| SCHEMBL2006542 | 0.84 | CPT1A (0.53) | CPT1ARORCCYP2C9CPT2CPT1B | |
| SCHEMBL2000593 | 0.84 | CPT1A (0.51) | CPT1ARORCALDH1A1CYP2C9NAMPT | |
| SCHEMBL2005371 | 0.84 | CPT1A (0.53) | CPT1ARORCCYP2C9CPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | CPT1A 3067/4885RORC 122/4885ALDH1A1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.